Atezolizumab-bevacizumab may change the treatment landscape of liver cancer
04 Sep 2020
byAudrey Abella
Safety data from the phase III IMbrave150 trial reinforce the previously reported favourable safety profile of atezolizumab-bevacizumab compared with sorafenib for unresectable hepatocellular carcinoma (HCC).
Atezolizumab-bevacizumab may change the treatment landscape of liver cancer
04 Sep 2020
